Beyond Standard Endocrine Therapy: A New Adjuvant Treatment in High-Risk Early Breast Cancer.

The standard adjuvant treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) is endocrine therapy (ET). Despite this treatment, 20% of patients will have their disease recur. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors with ET have shown overall survival (OS) benefit in ER-positive, HER2-negative breast cancer in the metastatic setting.

Glutamate concentrations and cognitive deficits in ultra-treatment-resistant schizophrenia: An exploratory and comparative H-MRS study.

Background And Aims: Glutamate plays a crucial role in cognition, learning, and mood regulation, with studies suggesting glutamatergic dysfunction in chronic schizophrenia. This study explored glutamate levels in the occipital cortex (OCC) and cognitive function in ultra-treatment resistant schizophrenia (uTRS) compared to healthy controls.

Methods: Fifteen uTRS participants and 19 healthy controls underwent 3T proton magnetic resonance spectroscopy (H-MRS) to measure glutamate levels in the OCC.

IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia.

Cobenfy, a co-formulation of xanomeline and trospium, is the first drug not acting on the dopaminergic system of the CNS approved for the treatment of schizophrenia by the FDA. Xanomeline is a muscarinic M1 and M4 receptor (CHRM1 and CHRM4) agonist whilst trospium is a peripherally active CHRM antagonist that reduces the unwanted peripheral side-effects of xanomeline. Relevant to this exciting development, this review details the human CNS cholinergic systems and how those systems are affected by the molecular pathology of schizophrenia in a way suggesting activating the CHRM1 and 4 would be beneficial in treating the disorder.

A scoping review to map public-facing websites for non-traumatic wrist disorders with quality evaluation.

Introduction: Public-facing resources for non-traumatic wrist disorders (NTWD) exist, but care recipients and healthcare professionals alike are uncertain where to access the most useful resources and have raised concerns over the quality of information provided. Previous studies involving stakeholders highlight a need for quality evaluation of these resources. The aim of this study was to identify website resources accessible to UK-based online health seekers and explore their content through quality assessment.